
Current approaches to survey tumor and immune evasion mechanisms have focused on tumor and T-cell receptor sequencing. Whole-exome sequencing of plasma cell-free DNA (WES-cfDNA) combines the advantages of longitudinal follow-up by liquid biopsy with genomic sequencing and is an emerging candidate approach to monitor the dynamics of tumor evolution and inform treatment decisions.
Like
Save
Share